Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance

Journal of Medicinal Chemistry

Volumn 60, Issue 7, 2017, Pages 2930-2943

  Qiu, Qianqian ^a   Shi, Wei ^a   Li, Zheng ^a   Zhang, Bo ^a   Pan, Miaobo ^a   Cui, Jian ^a   Dai, Yuxuan ^a   Huang, Wenlong ^a   Qian, Hai ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(PYRIDIN 4 YLMETHYL)AMINO] N(1,2,3,4 TETRAHYDRONAPHTHALEN 1 YL)NICOTINAMIDE; 2 [(PYRIDIN 4 YLMETHYL)AMINO] N(3,4,5 TRIMETHOXYPHENYL)NICOTINAMIDE; 2 [(PYRIDIN 4 YLMETHYL)AMINO] N[2 (THIOPHEN 2 YL)ETHYL]NICOTINAMIDE; 2 [(PYRIDIN 4 YLMETHYL)AMINO] N[4 (TRIFLUOROMETHOXY)PHENYL]NICOTINAMIDE; MULTIDRUG RESISTANCE PROTEIN; N BENZHYDRYL 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N(1H BENZO[D]IMIDAZOL 2 YL) 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N(2 BENZOYLPHENYL) 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N(3 CHLORO 4 FLUOROPHENYL) 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N(3 CHLORO 4 METHOXYPHENYL) 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N(3 METHOXYPHENYL) 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N(3,4 DIMETHOXYBENZYL) N METHYL 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N(3,4 DIMETHOXYPHENETHYL) 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N(4 MORPHOLINOPHENYL) 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N(9H FLUOREN 2 YL) 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N(NAPHTHALEN 1 YL) 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N(PYRIDIN 4 YLMETHYL) 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N,N DIBENZYL 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; NICOTINAMIDE DERIVATIVE; N[(1,1' BIPHENYL) 4 YL] 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N[4 (4 METHYLPIPERAZIN 1 YL)PHENYL] 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N[4 (PIPERIDIN 1 YL)PHENYL] 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N[4 (TERT BUTYL)PHENYL] 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; N[5 (3 METHOXYPHENYL) 1,3,4 THIADIAZOL 2 YL] 2 [(PYRIDIN 4 YLMETHYL)AMINO]NICOTINAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [1 (FURAN 2 YL) 6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H)YL][2 [(PYRIDIN 4 YLMETHYL)AMINO]PYRIDIN 3 YL]METHANONE; [1 (TERT BUTYL) 6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H)YL][2 [(PYRIDIN 4 YLMETHYL)AMINO]PYRIDIN 3 YL]METHANONE; [1,4' BIPIPERIDIN] 1' YL[2 [(PYRIDIN 4 YLMETHYL)AMINO]PYRIDIN 3YL]METHANONE; [6,7 DIMETHOXY 1 PHENYL 3,4 DIHYDROISOQUINOLIN 2(1H) YL][2 [(PYRIDIN 4 YLMETHYL)AMINO]PYRIDIN 3 YL]METHANONE; [6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL][2 [(PYRIDIN 4 YLMETHYL)AMINO]PYRIDIN 3 YL]METHANONE; ANTINEOPLASTIC ANTIBIOTIC; CYTOCHROME P450 3A; DOXORUBICIN; NICOTINAMIDE;

ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; EC50; HUMAN; HUMAN CELL; IC50; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG RESISTANCE; K-562 CELL LINE; METABOLISM; NEOPLASMS;

ANTIBIOTICS, ANTINEOPLASTIC; CYTOCHROME P-450 CYP3A; DOXORUBICIN; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; K562 CELLS; NEOPLASMS; NIACINAMIDE; P-GLYCOPROTEIN;

EID: 85017530771     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01879     Document Type: Article

References (55)

1. Gottesman, M. M. Mechanisms of cancer drug resistance Annu. Rev. Med. 2002, 53, 615-627 10.1146/annurev.med.53.082901.103929
2. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of p-glycoprotein reveals a molecular basis for poly-specific drug binding Science 2009, 323, 1718-1722 10.1126/science.1168750
3. Jin, M. S.; Oldham, M. L.; Zhang, Q.; Chen, J. Crystal structure of the multidrug transporter p-glycoprotein from caenorhabditis elegans Nature 2012, 490, 566-569 10.1038/nature11448
4. Martinez, L.; Arnaud, O.; Henin, E.; Tao, H.; Chaptal, V.; Doshi, R.; Andrieu, T.; Dussurgey, S.; Tod, M.; Di Pietro, A.; Zhang, Q.; Chang, G.; Falson, P. Understanding polyspecificity within the substrate-binding cavity of the human multidrug resistance p-glycoprotein FEBS J. 2014, 281, 673-682 10.1111/febs.12613
5. Susa, M.; Choy, E.; Yang, C.; Schwab, J.; Mankin, H.; Hornicek, F.; Duan, Z. Multidrug resistance reversal agent, nsc77037, identified with a cell-based screening assay J. Biomol. Screening 2010, 15, 287-296 10.1177/1087057109359422
6. Szakács, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer Nat. Rev. Drug Discovery 2006, 5, 219-234 10.1038/nrd1984
7. Wong, K.; Ma, J.; Rothnie, A.; Biggin, P. C.; Kerr, I. D. Towards understanding promiscuity in multidrug efflux pumps Trends Biochem. Sci. 2014, 39, 8-16 10.1016/j.tibs.2013.11.002
8. Varma, M. V.; Ashokraj, Y.; Dey, C. S.; Panchagnula, R. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement Pharmacol. Res. 2003, 48, 347-359 10.1016/S1043-6618(03)00158-0
9. Wang, R.; Kuo, C.; Lien, L.; Lien, E. Structure-activity relationship: Analyses of p-glycoprotein substrates and inhibitors J. Clin. Pharm. Ther. 2003, 28, 203-228 10.1046/j.1365-2710.2003.00487.x
10. Yang, K.; Wu, J.; Li, X. Recent advances in research on p-glycoprotein inhibitors Biosci. Trends 2008, 2, 137-146
11. Mayur, Y.; Peters, G.; Rajendra Prasad, V.; Lemos, C.; Sathish, N. Design of new drug molecules to be used in reversing multidrug resistance in cancer cells Curr. Cancer Drug Targets 2009, 9, 298-306
12. Ernst, R.; Kueppers, P.; Stindt, J.; Kuchler, K.; Schmitt, L. Multidrug efflux pumps: Substrate selection in atp-binding cassette multidrug efflux pumps-first come, first served? FEBS J. 2010, 277, 540-549 10.1111/j.1742-4658.2009.07485.x
13. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of vincristine resistance in p388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Cancer Res. 1981, 41, 1967-1972
14. Slater, L. M.; Sweet, P.; Stupecky, M.; Gupta, S. Cyclosporin a reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro J. Clin. Invest. 1986, 77, 1405 10.1172/JCI112450
15. Mickisch, G.; Noordzij, M.; vd Gaast, A.; Gebreamlack, P.; Köhrmann, K.; Mogler-Drautz, E.; Kupper, H.; Schröder, F. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma J. Cancer Res. Clin. Oncol. 1995, 121, R11-R16 10.1007/BF02351065
16. Kusunoki, N.; Takara, K.; Tanigawara, Y.; Yamauchi, A.; Ueda, K.; Komada, F.; Ku, Y.; Kuroda, Y.; Saitoh, Y.; Okumura, K. Inhibitory effects of a cyclosporin derivative, sdz psc 833, on transport of doxorubicin and vinblastine via human p-glycoprotein Jpn. J. Cancer Res. 1998, 89, 1220-1228 10.1111/j.1349-7006.1998.tb00518.x
17. Fox, E.; Bates, S. E. Tariquidar (xr9576): A p-glycoprotein drug efflux pump inhibitor Expert Rev. Anticancer Ther. 2007, 7, 447-459 10.1586/14737140.7.4.447
18. Dantzig, A.; Law, K.; Cao, J.; Starling, J. Reversal of multidrug resistance by the p-glycoprotein modulator, ly335979, from the bench to the clinic Curr. Med. Chem. 2001, 8, 39-50 10.2174/0929867013373903
19. Robert, J.; Jarry, C. Multidrug resistance reversal agents J. Med. Chem. 2003, 46, 4805-4817 10.1021/jm030183a
20. Martelli, C.; Coronnello, M.; Dei, S.; Manetti, D.; Orlandi, F.; Scapecchi, S.; Novella Romanelli, M.; Salerno, M.; Mini, E.; Teodori, E. Structure- activity relationships studies in a series of n, n-bis (alkanol) amine aryl esters as p-glycoprotein (pgp) dependent multidrug resistance (mdr) inhibitors J. Med. Chem. 2010, 53, 1755-1762 10.1021/jm9016174
21. Palmeira, A.; Sousa, E.; Vasconcelos, M. H.; Pinto, M. M. Three decades of p-gp inhibitors: Skimming through several generations and scaffolds Curr. Med. Chem. 2012, 19, 1946-2025 10.2174/092986712800167392
22. Kathawala, R. J.; Gupta, P.; Ashby, C. R., Jr.; Chen, Z. S. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade Drug Resist. Updates 2015, 18, 1-17 10.1016/j.drup.2014.11.002
23. Kim, J. C.; Kim, K. S.; Kim, D. S.; Jin, S. G.; Kim, D. W.; Kim, Y. I.; Park, J.-H.; Kim, J. O.; Yong, C. S.; Youn, Y. S.; Woo, J. S.; Choi, H.-G. Effect of hm30181 mesylate salt-loaded microcapsules on the oral absorption of paclitaxel as a novel p-glycoprotein inhibitor Int. J. Pharm. 2016, 506, 93-101 10.1016/j.ijpharm.2016.04.034
24. Zou, W.; Sarisozen, C.; Torchilin, V. P. The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles J. Drug Targeting 2017, 25, 225-234 10.1080/1061186X.2016.1236113
25. Bauer, M.; Blaickner, M.; Philippe, C.; Wadsak, W.; Hacker, M.; Zeitlinger, M.; Langer, O. Whole-body distribution and radiation dosimetry of 11c-elacridar and 11c-tariquidar in humans J. Nucl. Med. 2016, 57, 1265-1268 10.2967/jnumed.116.175182
26. Srinivas, N. R. Understanding the role of tariquidar, a potent pgp inhibitor, in combination trials with cytotoxic drugs: What is missing? Cancer Chemother. Pharmacol. 2016, 78, 1097-1098 10.1007/s00280-016-3044-4
27. Kim, J. C.; Kim, K. S.; Dong, S. K.; Jin, S. G.; Kim, D. W.; Kim, Y. I.; Park, J.-H.; Kim, J. O.; Yong, C. S.; Youn, Y. S.; Woo, J. S.; Choi, H.-G. Effect of HM30181 mesylate salt-loaded microcapsules on the oral absorption of paclitaxel as a novel p-glycoprotein inhibitor Int. J. Pharm. 2016, 506, 93-101 10.1016/j.ijpharm.2016.04.034
28. Milano, G.; Spano, J.; Leyland-Jones, B. Egfr-targeting drugs in combination with cytotoxic agents: From bench to bedside, a contrasted reality Br. J. Cancer 2008, 99, 1-5 10.1038/sj.bjc.6604373
29. Shukla, S.; Chen, Z. S.; Ambudkar, S. V. Tyrosine kinase inhibitors as modulators of abc transporter-mediated drug resistance Drug Resist. Updates 2012, 15, 70-80 10.1016/j.drup.2012.01.005
30. Chen, C. Y.; Liu, N. Y.; Lin, H. C.; Lee, C. Y.; Hung, C. C.; Chang, C. S. Synthesis and bioevaluation of novel benzodipyranone derivatives as p-glycoprotein inhibitors for multidrug resistance reversal agents Eur. J. Med. Chem. 2016, 118, 219-229 10.1016/j.ejmech.2016.03.070
31. Pati, M. L.; Abate, C.; Contino, M.; Ferorelli, S.; Luisi, R.; Carroccia, L.; Niso, M.; Berardi, F. Deconstruction of 6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline moiety to separate p-glycoprotein (p-gp) activity from σ 2 receptor affinity in mixed p-gp/σ 2 receptor agents Eur. J. Med. Chem. 2015, 89, 691-700 10.1016/j.ejmech.2014.11.001
32. Mi, Y. J.; Liang, Y. J.; Huang, H. B.; Zhao, H. Y.; Wu, C. P.; Wang, F.; Tao, L. Y.; Zhang, C. Z.; Dai, C. L.; Tiwari, A. K.; Ma, X. X.; To, K. K.; Ambudkar, S. V.; Chen, Z. S.; Fu, L. W. Apatinib (yn968d1) reverses multidrug resistance by inhibiting the efflux function of multiple atp-binding cassette transporters Cancer Res. 2010, 70, 7981-7991 10.1158/0008-5472.CAN-10-0111
33. Wang, Y. J.; Kathawala, R. J.; Zhang, Y. K.; Patel, A.; Kumar, P.; Shukla, S.; Fung, K. L.; Ambudkar, S. V.; Talele, T. T.; Chen, Z. S. Motesanib (amg706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the abcb1 Biochem. Pharmacol. 2014, 90, 367-378 10.1016/j.bcp.2014.06.006
34. Dominguez, C.; Smith, L.; Huang, Q.; Yuan, C.; Ouyang, X.; Cai, L.; Chen, P.; Kim, J.; Harvey, T.; Syed, R.; Kim, T. S.; Tasker, A.; Wang, L.; Zhang, M.; Coxon, A.; Bready, J.; Stames, C.; Chen, D.; Gan, Y.; Neervannan, S.; Kumar, G.; Polverino, A.; Kendall, R. Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr Bioorg. Med. Chem. Lett. 2007, 17, 6003-6008 10.1016/j.bmcl.2007.07.077
35. Huang, M.; Lin, X.; Zhu, X.; Peng, W.; Xie, J.; Wan, Y. A highly versatile catalytic system for n-arylation of amines with aryl chlorides in water Eur. J. Org. Chem. 2011, 2011, 4523-4527 10.1002/ejoc.201100458
36. Mistry, P.; Stewart, A. J.; Dangerfield, W.; Okiji, S.; Liddle, C.; Bootle, D.; Plumb, J. A.; Templeton, D.; Charlton, P. In vitro and in vivo reversal of p-glycoprotein-mediated multidrug resistance by a novel potent modulator, xr9576 Cancer Res. 2001, 61, 749-758
37. Chan, K.-F.; Wong, I. L.; Kan, J. W.; Yan, C. S.; Chow, L. M.; Chan, T. H. Amine linked flavonoid dimers as modulators for p-glycoprotein-based multidrug resistance: Structure-activity relationship and mechanism of modulation J. Med. Chem. 2012, 55, 1999-2014 10.1021/jm201121b
38. Dantzig, A. H.; Shepard, R. L.; Cao, J.; Law, K. L.; Ehlhardt, W. J.; Baughman, T. M.; Bumol, T. F.; Starling, J. J. Reversal of p-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, ly335979 Cancer Res. 1996, 56, 4171-4179
39. Ludescher, C.; Thaler, J.; Drach, D.; Drach, J.; Spitaler, M.; Gattringer, C.; Huber, H.; Hofmann, J. Detection of activity of p-glycoprotein in human tumour samples using rhodamine 123 Br. J. Haematol. 1992, 82, 161-168 10.1111/j.1365-2141.1992.tb04608.x
40. Chaudhary, P. M.; Mechetner, E. B.; Roninson, I. Expression and activity of the multidrug resistance p-glycoprotein in human peripheral blood lymphocytes Blood 1992, 80, 2735-2739
41. Sharom, F. J.; Yu, X.; Chu, J. W.; Doige, C. A. Characterization of the atpase activity of p-glycoprotein from multidrug-resistant chinese hamster ovary cells Biochem. J. 1995, 308, 381-390 10.1042/bj3080381
42. Ambudkar, S. V.; Dey, S.; Hrycyna, C. A.; Ramachandra, M.; Pastan, I.; Gottesman, M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter 1 Annu. Rev. Pharmacol. Toxicol. 1999, 39, 361-398 10.1146/annurev.pharmtox.39.1.361
43. Jabbar, S.; Twentyman, P.; Watson, J. The mtt assay underestimates the growth inhibitory effects of interferons Br. J. Cancer 1989, 60, 523 10.1038/bjc.1989.306
44. Chen, L. M.; Wu, X. P.; Ruan, J. W.; Liang, Y. J.; Ding, Y.; Shi, Z.; Wang, X. W.; Gu, L. Q.; Fu, L. W. Screening novel, potent multidrug-resistant modulators from imidazole derivatives Oncol. Res. 2004, 14, 355-362
45. Wang, N. N.; Zhao, L. J.; Wu, L. N.; He, M. F.; Qu, J. W.; Zhao, Y. B.; Zhao, W. Z.; Li, J. S.; Wang, J. H. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line Asian Pac. J. Cancer Prev. 2013, 14, 4983-4988 10.7314/APJCP.2013.14.9.4983
46. Wong, I. L.; Chan, K.-F.; Tsang, K. H.; Lam, C. Y.; Zhao, Y.; Chan, T. H.; Chow, L. M. C. Modulation of multidrug resistance protein 1 (mrp1/abcc1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives J. Med. Chem. 2009, 52, 5311-5322 10.1021/jm900194w
47. Liu, B.; Qiu, Q.; Zhao, T.; Jiao, L.; Li, Y.; Huang, W.; Qian, H. 6, 7-dimethoxy-2-{2-[4-(1h-1, 2, 3-triazol-1-yl) phenyl] ethyl}-1, 2, 3, 4-tetrahydroisoquinolines as superior reversal agents for p-glycoprotein-mediated multidrug resistance ChemMedChem 2015, 10, 336-344 10.1002/cmdc.201402463
48. Ji, B. S.; He, L. Cjy, an isoflavone, reverses p-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (k562/dox) cells J. Pharm. Pharmacol. 2007, 59, 1011-1015 10.1211/jpp.59.7.0014
49. Chan, K. F.; Zhao, Y.; Burkett, B. A.; Wong, I. L.; Chow, L. M.; Chan, T. H. Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: Synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells J. Med. Chem. 2006, 49, 6742-6759 10.1021/jm060593+
50. Ambudkar, S. V. Drug-stimulatable atpase activity in crude membranes of human mdr1-transfected mammalian cells Methods Enzymol. 1998, 292, 504-514 10.1016/S0076-6879(98)92039-0
51. Stavrakov, G.; Keller, M.; Breit, B. From central to axial to central chirality: Enantioselective construction of the trans-4,5,9,10-tetrahydroxy-9,10-dihydrophenanthrene system Eur. J. Org. Chem. 2007, 2007, 5726-5733 10.1002/ejoc.200700583
52. Bradford, M. M. A rapid sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 1976, 72, 248-254 10.1016/0003-2697(76)90527-3
53. Dai, C. L.; Xiong, H. Y.; Tang, L. F.; Zhang, X.; Liang, Y. J.; Zeng, M. S.; Chen, L. M.; Wang, X. H.; Fu, L. W. Tetrandrine achieved plasma concentrations capable of reversing mdr in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice Cancer Chemother. Pharmacol. 2007, 60, 741-750 10.1007/s00280-007-0420-0
54. Kuramochi, M.; Fukuhara, H.; Nobukuni, T.; Kanbe, T.; Maruyama, T.; Ghosh, H. P.; Pletcher, M.; Isomura, M.; Onizuka, M.; Kitamura, T.; Sekiya, T.; Reeves, R. H.; Murakami, Y. Tslc1 is a tumor-suppressor gene in human non-small-cell lung cancer Nat. Genet. 2001, 27, 427-430 10.1038/86934
55. Dai, D.; Tang, J.; Rose, R.; Hodgson, E.; Bienstock, R. J.; Mohrenweiser, H. W.; Goldstein, J. A. Identification of variants of cyp3a4 and characterization of their abilities to metabolize testosterone and chlorpyrifos J. Pharmacol. Exp. Ther. 2001, 299, 825-831